Visits are snapshots
Most health data is captured in short appointments. What happens in the days and weeks between goes unseen.
UPSTRIQ™ HEALTH is building the missing layer in healthcare.
The detection window moves earlier.
Conceptual
We apply AI and machine learning to upstream drivers of health, passive data and clinical data to develop digital biomarkers and disease-specific risk forecasts across mental health, cardiometabolic, neurodevelopmental, cognitive and inflammatory conditions.
See what's upstream. Shape what's downstream.
Healthcare today is built to react. It responds once symptoms manifest, thresholds are crossed and damage is harder to reverse, because that is when the available measures show up. Clinicians act on what they can see. We help them see more, earlier.
Most health data is captured in short appointments. What happens in the days and weeks between goes unseen.
Sleep, stress, connection and other upstream drivers change well before a condition is named.
By the time a condition is named, the response is managing it, often with medication, when there is less room to change course.
Missed early
Conditions often go unrecognized or untreated for a long time.
If much of this disease can be changed earlier, the spending that follows it is the price of waiting.
The cost
What chronic and mental health conditions cost the U.S. system.
How common
How many people it reaches.
Most U.S. adults have at least one.
6 in 10
Driven by persistent, low-grade inflammation.
50%+
Chronic stress that outruns recovery.
76%
By condition
Where it concentrates.
Depression, anxiety, ADHD-related functioning, perinatal.
59.3M
Hypertension, heart failure, stroke, type 2 diabetes, obesity, fatty liver.
115.2M
Development, mild impairment and dementia; healthy aging, frailty and loss of reserve.
7.2M
UPSTRIQ™ Health is building a proprietary preventive health intelligence layer. Applied across these areas, our digital biomarkers and AI-powered predictive analytics are designed to forecast emerging risk and connect people to earlier intervention before disease develops or chronic illness worsens. These are our first areas of focus, and the same platform extends to other chronic conditions. Each follows the same pattern, where upstream drivers become signals, signals become forecasts and forecasts lead to earlier action.
Identify changes in behavioral and daily-life signals that may indicate emerging mental health risk, supporting earlier assessment and intervention.
Connect upstream drivers with physiological and clinical signals to identify emerging cardiometabolic risk and inform preventive action.
Track changes in cognitive and behavioral patterns to help identify emerging concerns and support earlier evaluation.
Integrate daily-life and clinical data to investigate patterns associated with inflammation and inform earlier risk assessment.
Explore patterns in attention, sleep, behavior and daily functioning to better understand individual needs and support earlier assessment and personalized care.
About 91% of U.S. adults own a smartphone; nearly a third track health with a wearable.[13][14]
Connected clinical data under federal interoperability rules.[15]
Prevention and value-based care, including CMS's goal of accountable care for all Traditional Medicare beneficiaries by 2030.[16]
Our platform bridges the gap between fragmented health data and actionable clinical foresight. By meeting the rigorous validation standards required by federal health innovation initiatives, UPSTRIQ™ delivers scalable solutions designed to eliminate health disparities and protect populations at scale.
“We aren’t just predicting the future of health. We are giving individuals and healthcare systems the window of time needed to change it.”Shilpa Parikh, MBA · Founder & CEO, UPSTRIQ™ HEALTH
Assessments, wearables and clinical risk tools each see one part, often once disease is underway. UPSTRIQ is designed to connect all three over time.
Trust and fit
Every measure, biomarker and model is validated for its intended population and use.
Complements the devices and systems customers already use, and exchanges data with them in both directions via API.
Who benefits
Earlier action on emerging risk, before disease develops, function declines or chronic illness worsens.
Upstream health insight for employers, universities and programs, with participant tracking and de-identified reporting.
Designed to lower costs by moving intervention upstream of acute care and costly complications.
The first validation study, ASPEN™, is in process.
Patient tracking between visits and earlier risk insight for care teams.
Who we servePopulation risk insight, designed to move intervention upstream of costly care.
Who we serveHelp validate the science and extend it to new populations and conditions.
Our researchSupport a company building the missing layer in healthcare.
Investor overviewChronic disease leaves footprints years before diagnosis. We measure and learn from them.
Conceptual · not patient data
Sleep that stops restoring. Stress that stops resetting. Connection that thins. While each is small alone, when measured together over time they may be used to forecast risk of chronic disease, perhaps early enough to intervene and change the trajectory. We are validating to earn each claim.
Repeated stress can build allostatic load and chronic inflammation, linked to many chronic diseases. UPSTRIQ™ measures at the first step.
Sympathetic nerves Adrenaline
Cortisol feedback, weakened by chronic stress
Building Burden
Cortisol · DHEA-S (low) · Adrenaline
Systolic BP · Diastolic BP
HbA1c · Waist-to-hip ratio · HDL (low)
* MacArthur markers. Examples, not a full panel.
Immune cells stop responding to cortisol (glucocorticoid resistance)
UPSTRIQ™ starts measuring here
Research panels,
once, at a visit
Allostatic load is the wear and tear when the body's stress adjustments are demanded too often or last too long (McEwen, 1998).
Frequent stressors, no recovery between.
A full reaction to the same stressor, every time.
The response does not shut off when the stressor ends.
Too little cortisol, so inflammation overreacts.
The MacArthur studies combined ten markers into one score (Seeman et al., 1997); later work adds CRP and IL-6.
These panels are one-time snapshots. Our candidate MUDH™ Biomarkers for Load, Recovery and Capacity aim to track strain and recovery continuously, and will be tested against an independent clinical reference.
The strain carried: stress, poor sleep, isolation, digital overload, substance use and diet.
The return to baseline. Without it, the same load does more harm.
The reserve to adapt. A planned future measure.
MUDH™ Signals (self-report, passive, wearable and clinical data) → candidate MUDH™ Biomarkers for Load, Recovery and Capacity, validated against clinical reference measures.
When recovery stays incomplete, stress systems can stay on, immune cells can tune out cortisol and low-grade inflammation can persist: a shared pathway to many chronic conditions.
stress, poor sleep, isolation
body doesn't return to baseline
planned future measure
HPA axis (cortisol) and sympathetic nervous system
glucocorticoid receptor resistance
IL-6 · CRP · TNF-α
Feedback: inflammation disrupts sleep, mood and energy, adding load and slowing recovery
Peer-reviewed research behind each MUDH™ Vital and the allostatic load pathway.
One architecture connecting measurement, biomarkers, forecasting, intervention and follow-up.
MUDHIVA™ is focused on leading the paradigm shift: moving from reactive care to proactive, personalized and preventive health.
The MUDH™ Index scores 0 to 100; MUDH™ Vitals show which Vitals changed.
MUDH™ VitalsEach MUDH™ instrument is validated for a specified population and use.
ASPEN™, the first validation study, is in process.*
*ASPEN™ is validating the MUDH™ scale for reliability and validity.
MUDH™ Signals adds phone, wearable and clinical data to MUDH™ measurement, tracking change continuously against each person's own baseline, not only at visits.
Passive or wearable signal MUDH™ Vital from monthly check-in
UPSTRIQ™ is developing proprietary MUDH™ candidate digital biomarkers, with planned studies to evaluate their validity for defined populations and intended uses.
Predictive models turn each person's trajectory into a disease-specific forecast for a defined outcome and time window, so care can start earlier.
MUDH™ Index against this person's own baseline, with Load and Recovery.
18% sit in the Elevated or Critical Trajectory bands and are routed for review.
Care-team review recommended · sleep plan shared
Illustrative example. Names, values and forecasts are not patient data.
Built for the people who act on them, each with patient tracking over time.
Patients also see their own results, trends and next steps. Dashboard images are concept designs.
Repeat measurement after care.
What happened, recorded over time.
How instruments, biomarkers and models performed.
Updates validated before deployment.
One measurement layer and validation method, applied population by population.
A new population or condition adds a validated forecast, not a new platform.
| Product | What it does | Current status | Validation | Next |
|---|---|---|---|---|
| MUDH™ instruments | PRO/ePRO assessment and screening, eight Vitals | Core instrument developed (versioned scoring) | Validation study in process (ASPEN™) | Population-specific instruments |
| MUDH™ Monitor | Tracks the MUDH Index and Vitals over time | Building | — | Expanded longitudinal views |
| MUDH™ Signals | MUDH™ Biomarkers for Load, Recovery and Capacity | — | — | Load, Recovery and Capacity |
| Risk forecasting | Disease-specific AI/ML models | — | — | Models for priority applications |
| Navigator | Risk bands, alerts, clinical review and routing | — | — | Framework planned |
| Dashboards | Enterprise, healthcare and payer views | Concept designs; planned | — | Planned |
| Integrations | SMART on FHIR, APIs, partner connections | SMART on FHIR application | — | APIs and partner integrations |
| Integrated system | The connected closed loop | — | — | Planned |
Status as of October 2026.
HIPAA-compliant infrastructure with consent and permitted-use controls.
Cloud software designed to scale from pilot to enterprise.
Role-based access, secure data exchange and de-identified research data.
API-ready, with a SMART on FHIR app for EHRs.
Use each product alone or together, by availability and intended use.
How each customer puts MUDHIVA™ to work.
Identify participants on emerging risk trajectories and track change between study visits with MUDH™ Signals.
Employers and universities see upstream health trends early and connect people to support, with de-identified reporting.
Care teams follow the MUDH™ Index, MUDH™ Vitals and risk forecasts between visits and act before patients deteriorate.
Health plans prioritize members for early outreach and prevention programs, designed to reduce avoidable acute care.
Agencies and programs track upstream drivers across populations to target prevention where it is needed most.
Measure the modifiable upstream determinants of health.
Opportunities to pilot our MUDH™ are opening and ongoing.
MUDH™ Signals: passive and clinical data that measure continuous change.
Predictive models that forecast chronic disease risk.
Navigator stratifies risk and connects people to the right response.
Each includes patient tracking over time.
Licensing, APIs and a SMART on FHIR app. Partners plug in, not rebuild.
Where we start. See the need behind each on the home page.
Earlier recognition of mental health risk, and connection to care.
Risk forecasting across pregnancy and postpartum, linked to intervention.
Earlier recognition of cardiometabolic risk, and intervention, from upstream, daily-life and clinical data.
Tracking with the MUDH™ Index and MUDH™ Vitals.
Load, Recovery and Capacity biomarkers.
First disease-specific models in our three priority applications.
Risk bands linked to validated online interventions and partner care.
More conditions, including cognitive and inflammatory, at every age.
UPSTRIQ™ HEALTH is a preventive health intelligence company, combining upstream health measurement with wearable, smartphone and clinical data to forecast chronic disease risk and connect people to earlier intervention.
Experience across drug, diagnostics and device development, clinical research, data science and commercialization.
Led by a founder with 30+ years in drug, diagnostics and device development.*
*Founder's prior-company career. Not UPSTRIQ figures.
Clinical & Scientific Advisors and a Commercial Advisory Board guide evidence and adoption.
COSMIN · V3 · TRIPOD+AI · predefined go/no-go gates · de-identified research data · SMART on FHIR · safeguards designed to support HIPAA requirements.
Make preventive health intelligence part of everyday care, enabling action before disease develops, function declines, or chronic illness worsens.
UPSTRIQ™ HEALTH is a Delaware C corporation headquartered in Palo Alto, California, where healthcare, research and technology meet.
30+ years in drug, diagnostics and device development. Launched 12+ products, generating $22B+ in revenue and $41B+ in exits at prior companies. Brings healthcare and technology together, with a BS in Computer Engineering from the University of Michigan and an MBA from Carnegie Mellon’s Tepper School of Business.
27+ years in corporate finance, strategic operations, fundraising and organizational growth, including supporting biotechnology companies such as Genentech and Relypsa. Builds the financial, operational and governance infrastructure for complex, multi-institutional programs.
Senior technology product executive, previously Chief Product Officer at Alegion and EVP of Product at MTPV Power, with earlier leadership roles at Unisys, HP and Acer. Leads the data layer and passive-data implementation.
Strategy and commercialization executive with 25+ years in growth, brand, innovation and market strategy, including senior roles at P&G and Nestlé and advisory work for IBM, AT&T, Huawei and Caesars Entertainment. Leads corporate strategy, commercialization and strategic partnerships.
Technology executive with 30+ years leading digital transformation in life sciences: AI, data and analytics, cloud, cybersecurity and regulatory compliance. Senior technology roles at IGM Biosciences, Cytokinetics, Pharmacyclics/AbbVie and Johnson & Johnson.
Physician with 20+ years across internal medicine, infectious diseases, public health and implementation science, including work with the CDC, WHO and Washington University. Brings clinical rigor and implementation readiness to every program.
Vice President, Global Program Lead, Bristol Myers Squibb · cardiovascular development
Louis W. Menk Professor of Psychology, Northwestern University · Co-Director, Foundations of Health Research Center
Senior AI Engineer, Databricks
Mental health therapist and behavioral interventionist
Computational Psychologist and AI Researcher
Payer, market and commercial guidance.
Head of Corporate Development, Bench International
Founder, President & CEO, D2 Solutions · former VP of Sales and Marketing, Express Scripts Specialty Pharmacy Benefits Management · prior roles at U.S. Healthcare and Cardinal Health
Co-Founder, FirstMileBio · Founder, Cogent Healthcare
Independent Biopharma Commercial Consultant · formerly Commercial Leadership Team, Cytokinetics
CEO, Blooming Peak Eastern Medical
We are planning paid pilots with care-delivery partners, starting with 90-day programs that pair MUDH™ measurement with longitudinal monitoring. Pilot letters of intent have been received from four organizations.
Opportunities, eligibility, areas of contribution and how to apply.
How we develop and validate our proprietary technology, layer by layer.
Nothing advances until it clears its pre-set GO criterion.
Psychometrics, reliability, responsiveness.
GO: ω ≥ 0.80 · ICC ≥ 0.70Feature stability, reference biology and clinical change.
GO: ICC ≥ 0.70 + held-out associationLocked disease-specific models, calibration, external test.
GO: ΔAUROC ≥ 0.05 or +NRI · calibration 0.8–1.2Repeat measurement, reviewed alerts, intervention capture.
GO: ≥70% repeat measurement + workflow completionNO-GO means revise or stop. We do not market a failed claim.
Status as of October 2026.
| Program | Population | Objective | Status |
|---|---|---|---|
| MUDH™ measuring system | Adults | Evaluate PRO and ePRO reliability and validity | Validation study in process (ASPEN™, October 2026) |
| Adolescent mental health | Adolescents | Earlier recognition of changing mental health and functioning | Planned |
| Pregnancy and postpartum health | Pregnant and postpartum people | Emerging risk of depression, anxiety, hypertensive disorders and gestational diabetes | Planned |
| Cardiometabolic health | Adults | Earlier recognition of changing cardiometabolic risk | Planned |
| Load and Recovery biomarkers | Adults | Digital biomarkers of sustained load and recovery | Planned |
We partner with academic, clinical and industry teams on every validation layer and on clinical evaluation.
Initial focus: care-delivery organizations with longitudinal prevention or chronic-condition programs, starting with virtual and specialty care.
First commercial milestones are planned on the equity path and do not depend on grants.
Status: ARPA-H and NIH SBIR applications under review. No awards have been made.
Provisional patent applications filed; software, instruments and methods held as trade secrets.
The research behind MUDH™, the Modifiable Upstream Determinants of Health: key studies by Vital, an allostatic load primer and the full reference library.
UPSTRIQ publications: none yet. Results will be listed here as studies are reported.
Each Vital is modifiable and linked in peer-reviewed research to chronic disease, mental health or mortality.
Optimism was associated with a 35% lower risk of cardiovascular events across ~230,000 people.
[22] Rozanski et al. · JAMA Netw Open, 2019
Read the study →Social threat activates inflammation that can drive depressive symptoms. [9] Slavich & Irwin · Psychol Bull, 2014 · Read →
Job strain carried ~23% higher coronary heart disease risk across ~197,000 people.
[23] Kivimäki et al. · Lancet, 2012
Read the study →More than 3 hours a day of social media was linked to later depression and anxiety in ~6,600 adolescents.
[24] Riehm et al. · JAMA Psychiatry, 2019
Read the study →Stronger social relationships: ~50% greater likelihood of survival across 148 studies.
[13] Holt-Lunstad, Smith & Layton · PLoS Med, 2010
Read the study →Poor diet was linked to ~11 million deaths in 2017, more than any other risk factor.
[25] GBD 2017 Diet Collaborators · Lancet, 2019
Read the study →Physical inactivity accounts for 6–10% of several major chronic diseases and ~9% of premature deaths.
[26] Lee et al. · Lancet, 2012
Read the study →Both short and long habitual sleep are associated with higher mortality.
[27] Cappuccio et al. · Sleep, 2010
Read the study →Alcohol is the leading risk factor for death and disability among people aged 15–49.
[28] GBD 2016 Alcohol Collaborators · Lancet, 2018
Read the study →Higher allostatic load predicted later cardiovascular disease, decline and mortality in older adults.
[29] Seeman et al. · Arch Intern Med, 1997
Read the study →Inflammation-related diseases account for over half of deaths worldwide; chronic inflammation is linked to stress, sleep, diet, inactivity and isolation.
[30] Furman et al. · Nature Medicine, 2019
Read the study →The cumulative cost of repeated stress adaptation, and why it matters.
Your body is built to handle stress. Cortisol and adrenaline rise, the heart speeds up and energy is mobilized. This stability through change is called allostasis [1]; short term, it protects us [2].
The problem is repetition. When stress is frequent, prolonged or never switched off, the same systems wear us down. This cumulative cost is allostatic load [1][2]: the biological price of adapting, paid over years.
It can be measured by combining markers such as blood pressure, stress hormones, blood sugar, cholesterol and inflammation into one score. In the MacArthur studies of successful aging, this score predicted mortality and physical and cognitive decline better than any single marker [3]. Later reviews link it to cardiovascular, metabolic, cognitive and mental health outcomes [4][5].
It starts early. Childhood adversity is associated with higher allostatic load and age-related disease decades later [6]. Childhood stress appears to shape immune and stress responses for life [7].
So prevention must start upstream. Allostatic load builds long before diagnosis, and its drivers (chronic stress, poor sleep, isolation, diet, inactivity and substance use) are modifiable. The MUDH™ Vitals are designed to capture them. Load and Recovery, which are planned, are intended to show whether the body is resetting or falling behind, so change may be seen and acted on earlier.
Filter, or search by author, topic or finding. Links open the original source.
McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med, 1998.
Key finding: Stress mediators protect in the short term and damage over time.
Read the study →Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging. Psychol Bull, 2011.
Key finding: Childhood stress becomes embedded in biology and shapes later chronic disease risk.
Read the study →Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA, 2007.
Key finding: Chronic stress contributes to depression, cardiovascular disease and infection.
Read the study →Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol, 2018.
Key finding: Reviews how chronic stress raises cardiovascular risk.
Read the study →Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the ACE Study. Am J Prev Med, 1998.
Key finding: Early adversity tracked with adult disease and early death.
Read the study →Kivimäki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis. Lancet, 2012.
Key finding: Job strain ~23% higher CHD risk across ~197,000 people.
Read the study →McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med, 1993.
Key finding: Introduced "allostatic load" as the cumulative cost of chronic stress adaptation.
Read the study →Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. PNAS, 2001.
Key finding: A multi-system allostatic load score predicted mortality and decline better than single markers.
Read the study →Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev, 2010.
Key finding: Reviews allostatic load biomarkers and their links to health and cognition.
Read the study →Guidi J, Lucente M, Sonino N, Fava GA. Allostatic load and its impact on health: a systematic review. Psychother Psychosom, 2021.
Key finding: Links allostatic load to a broad range of physical and mental health outcomes.
Read the study →Danese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav, 2012.
Key finding: Connects early adversity to allostatic load and later age-related disease.
Read the study →Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. PNAS, 2012.
Key finding: Chronic stress reduced immune cells' response to cortisol, so inflammation was not switched off.
Read the study →Seeman TE, Singer BH, Rowe JW, Horwitz RI, McEwen BS. Price of adaptation: allostatic load and its health consequences. MacArthur studies of successful aging. Arch Intern Med, 1997.
Key finding: Higher allostatic load predicted later CVD, decline and mortality in older adults.
Read the study →Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med, 2019.
Key finding: Inflammation-related diseases account for over half of deaths worldwide; chronic inflammation is linked to stress, sleep, diet, inactivity and isolation.
Read the study →Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull, 2014.
Key finding: Social threat activates inflammation that can drive depressive symptoms.
Read the study →Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications. JAMA Psychiatry, 2015.
Key finding: People with mental disorders lose an estimated 10 years of potential life on average.
Read the study →Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005.
Key finding: Half of all lifetime mental disorders begin by age 14.
Read the study →Centers for Disease Control and Prevention. Youth Risk Behavior Survey: Data Summary & Trends Report, 2013–2023. CDC, 2024.
Key finding: 40% of high school students reported persistent sadness or hopelessness in 2023.
Read the study →Rozanski A, et al. Association of optimism with cardiovascular events and all-cause mortality: a systematic review and meta-analysis. JAMA Netw Open, 2019.
Key finding: Optimism was associated with a 35% lower risk of cardiovascular events across 15 studies and ~230,000 people.
Read the study →Riehm KE, Feder KA, Tormohlen KN, et al. Associations between time spent using social media and internalizing and externalizing problems among US youth. JAMA Psychiatry, 2019.
Key finding: >3 h/day of social media linked to later depression and anxiety in ~6,600 adolescents.
Read the study →Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis. Biol Psychiatry, 2016.
Key finding: Sleep disturbance associated with higher CRP and IL-6.
Read the study →Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis. Sleep, 2010.
Key finding: Short and long habitual sleep both associated with higher mortality.
Read the study →Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med, 2010.
Key finding: Stronger social relationships: ~50% greater likelihood of survival across 148 studies.
Read the study →Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke. Heart, 2016.
Key finding: Loneliness and isolation associated with higher CHD and stroke risk.
Read the study →GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017. Lancet, 2019.
Key finding: Poor diet linked to ~11 million deaths in 2017, more than any other risk factor.
Read the study →Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide. Lancet, 2012.
Key finding: Inactivity: 6–10% of several major chronic diseases, ~9% of premature deaths.
Read the study →GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016. Lancet, 2018.
Key finding: Alcohol: leading risk factor for death and disability ages 15–49.
Read the study →Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol, 2010.
Key finding: Defines the measurement properties UPSTRIQ™ validation is designed around.
Read the study →Insel TR. Digital phenotyping: technology for a new science of behavior. JAMA, 2017.
Key finding: Passive smartphone and sensor data can serve as continuous behavioral measures.
Read the study →Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology, 2016.
Key finding: Passive phone data can quantify behavior relevant to mental health.
Read the study →Goldsack JC, Coravos A, Bakker JP, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). npj Digit Med, 2020;3:55.
Key finding: Defines the three-part V3 framework for showing that a digital measure is fit for its intended use.
Read the study →FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016, updated.
Key finding: Standard definitions of biomarker types and validation terms used by FDA and NIH.
Read the study →Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ, 2024;385:e078378.
Key finding: Reporting standard for clinical prediction models, including those built with machine learning.
Read the study →No references match. Try another search or choose All.
connect@upstriq-health.com · 855 El Camino Real, Suite 13A #349, Palo Alto, CA 94301.
Bring one population, one outcome and one question. We'll discuss how upstream measurement could apply.
Build and evaluate models that turn digital biomarkers into risk forecasts.
Use wearable and phone data to track change against a personal baseline.
Support validation studies of the MUDH™ measuring system and its PRO/ePRO instruments.
Shape how people and care teams see trajectories and forecasts.
Map partners across payers, employers, health systems and life sciences.
Undergraduate and graduate students in computer science, data science, engineering, psychology, public health, medicine, design and business who care about prevention and take evidence seriously.
Email your resume and a short note on your area to connect@upstriq-health.com, subject "Internship".
How this website collects, uses and protects information. Last updated October 2026.
This policy covers the UPSTRIQ™ HEALTH website. Our assessment tools and research studies are governed separately by their own consent forms, data agreements and, where applicable, institutional review board (IRB) oversight.
When you request a briefing or email us, you share your name, organization, the type of organization you work with, your work email and your message. We use this only to respond, schedule a conversation and follow up on your request.
This website does not use cookies, analytics, advertising or tracking pixels. Like any website, the servers that deliver it may record standard technical logs, such as IP address, browser type, pages requested and time, to deliver and secure the site.
Our fonts load from Google Fonts, so Google receives your IP address and browser information when a page loads. Links to sources such as the CDC and NIH take you to sites governed by their own privacy policies.
We do not sell or rent personal information, and we do not share it for advertising.
We share contact information only with service providers who help us operate our email and website, under confidentiality obligations; when required by law; or as part of a merger, financing or acquisition, subject to this policy.
We keep inquiry correspondence as long as needed to respond and to maintain ordinary business records. You can ask us to delete it at any time.
This website does not collect health information. Please do not send personal health information through the briefing form or by email. Data from our assessment tools and studies is collected only with consent and is handled under the study's consent terms and our agreements with clinical and research partners.
This website is not directed to children under 13, and we do not knowingly collect their information. Studies involving adolescents are conducted with research partners under IRB oversight, with parental permission and adolescent assent.
We use reasonable safeguards to protect the information you send us. No method of transmission over the internet is completely secure.
You can ask to see, correct or delete the information you have sent us. Depending on where you live, such as California, you may have additional rights. Email connect@upstriq-health.com with "Privacy" in the subject line, and we will respond within a reasonable time. We will not treat you differently for making a request.
If we change how this website handles information, we will update this page and the date above.
This website provides general information about UPSTRIQ HEALTH and its work. By using it, you agree to these terms.
Content on this website is for information only. It is not medical advice and does not replace the judgment of a qualified clinician. UPSTRIQ assessment tools are investigational and are not FDA-cleared.
The website, its content and the UPSTRIQ and MUDH™ names and marks belong to UPSTRIQ HEALTH. You may not copy or reuse them without permission, except as allowed by law.
Links to outside sources are provided for reference. We are not responsible for their content.
The website is provided as is, without warranties of any kind, to the extent permitted by law.
We may update these terms. Questions: connect@upstriq-health.com.